Bayer’s newly announced $7.25 billion Roundup settlement is already facing serious resistance. On February 25, 2026, just eight days after the deal was made public, 14 law firms representing nearly 20,000 plaintiffs filed a motion to intervene in St. Louis City Circuit Court, asking Judge Timothy Boyer to delay preliminary approval by at least 60 days. Their core argument: the 600-plus page settlement package was dropped on them the same day it was announced, and a preliminary approval hearing was already on track for March 4 — giving attorneys just 15 days to review what could be one of the largest class action settlements in American history.
The stakes here are enormous. Consider an occupational claimant diagnosed with aggressive non-Hodgkin lymphoma before age 60 — under the proposed terms, that person would average roughly $165,000 in compensation. A residential user with the exact same diagnosis would receive an average of just $40,000. That four-to-one disparity is one of several structural concerns the objecting attorneys have raised about a deal they say was negotiated behind closed doors by a small group of plaintiffs’ lawyers over roughly two years.
Table of Contents
- Why Are Attorneys Seeking to Delay the $7.25 Billion Roundup Settlement Approval?
- What Would Preliminary Approval Actually Mean for Roundup Litigation?
- How the Compensation Tiers Create Winners and Losers
- What Should Current Roundup Claimants Do Right Now?
- The Release Provisions and What You Might Be Giving Up
- Bayer’s Position and the Road to Final Approval
- What Happens Next and Why It Matters Beyond Roundup
- Frequently Asked Questions
Why Are Attorneys Seeking to Delay the $7.25 Billion Roundup Settlement Approval?
The motion to intervene filed on February 25 centers on a straightforward procedural complaint: there was not enough time to review the deal. The 14 law firms told the court that receiving a 600-page settlement package and being expected to respond meaningfully within days is not how complex mass tort litigation should work. These are not fringe operators — they collectively represent nearly 20,000 of the approximately 65,000 remaining Roundup cancer claimants. Their requested remedy is a 60-day extension before any preliminary approval hearing takes place. The objecting firms also raised substantive concerns about the settlement’s structure.
They pointed out that the deal was negotiated without input from many of the attorneys who represent large numbers of Roundup plaintiffs. In mass tort settlements, exclusion from the negotiating table often means that the interests of certain plaintiff groups were not adequately represented. Compare this to the earlier Roundup multidistrict litigation settlements in 2020, where multiple rounds of objections and revisions played out over months before courts considered approval. There is also the question of absent class members — people who have been exposed to glyphosate-based Roundup but have not yet developed non-Hodgkin lymphoma. Under this settlement, their future legal rights could be significantly affected. If the court grants preliminary approval, those individuals may be bound by terms they never had a chance to evaluate, negotiated by lawyers they never hired.
What Would Preliminary Approval Actually Mean for Roundup Litigation?
If Judge Boyer grants preliminary approval, one of the most immediate and far-reaching consequences would be a broad stay of all Roundup litigation nationwide. That means every pending Roundup case — including lawsuits that have been working through the courts for nearly a decade — would be frozen while the settlement process plays out. For plaintiffs who are seriously ill and have waited years for their day in court, this is not a neutral procedural step. It could mean additional months or years of delay. The objecting attorneys argue this stay would prejudice sick plaintiffs who have already endured lengthy litigation.
However, if you are a claimant whose case is relatively new or who has not yet filed, the calculus is different — a settlement that offers guaranteed compensation, even at reduced amounts, may be preferable to the uncertainty and expense of individual litigation. The tradeoff depends entirely on the strength of your individual case, the severity of your diagnosis, and how long you are willing to wait. It is worth noting that Bayer has lost several high-profile Roundup trials, with jury verdicts reaching into the billions before being reduced on appeal. The company’s motivation to settle is clear: removing litigation risk. But for plaintiffs, accepting a settlement means giving up the possibility of a larger individual verdict. That is the fundamental tension at the heart of every mass tort class action, and it is especially sharp here given the compensation disparities built into the proposed tiers.
How the Compensation Tiers Create Winners and Losers
The settlement’s tiered compensation structure is one of the most contentious aspects of the deal. Under the proposed terms, an occupational user — someone who applied Roundup professionally, such as a farmworker or landscaper — diagnosed with aggressive non-Hodgkin lymphoma before age 60 could receive an average of $165,000. A residential user with the identical diagnosis would average $40,000. That is a striking gap, and the objecting attorneys have flagged it as evidence that the settlement was not designed with all claimants’ interests equally in mind. The distinction between occupational and residential exposure is not new in toxic tort litigation.
Courts and juries have long recognized that duration and intensity of exposure matter. But a $125,000 difference for the same cancer diagnosis raises questions about whether the residential tier adequately compensates people who may have used Roundup in their yards for decades. For a residential claimant with aggressive NHL, $40,000 may not cover even a fraction of treatment costs, lost wages, and pain and suffering. This kind of tier disparity is exactly why the objecting firms want more time. Without a thorough review of the settlement’s internal allocation formulas, it is impossible to know whether these averages reflect the full range of outcomes or whether certain categories of claimants are being systematically undervalued. The 600-page settlement document presumably contains the detailed criteria, but attorneys have not had adequate time to analyze it.
What Should Current Roundup Claimants Do Right Now?
If you are currently represented by an attorney in a Roundup lawsuit, the most important step is to contact your lawyer and ask directly whether your firm was involved in negotiating this settlement or whether it is among the 14 firms seeking a delay. That distinction matters because it tells you whether your interests were represented at the negotiating table. For claimants whose attorneys were part of the negotiating group, the settlement may move forward relatively quickly if preliminary approval is granted. For those represented by the objecting firms, the situation is more uncertain — your attorneys are actively fighting for more time and potentially better terms. Neither position is inherently better or worse.
A claimant with a strong individual case and an aggressive cancer diagnosis might benefit more from going to trial, where past Roundup verdicts have reached tens or hundreds of millions of dollars. A claimant with a weaker case or less severe diagnosis might prefer the certainty of a settlement payment, even a modest one. One thing all claimants should understand: if the court grants preliminary approval, you will eventually receive a notice explaining your options, including the right to opt out of the settlement and pursue your own lawsuit. Do not ignore that notice. The deadlines in class action settlements are strict, and missing them can permanently waive your rights.
The Release Provisions and What You Might Be Giving Up
Among the most serious concerns raised by the objecting attorneys are the settlement’s release provisions — the legal language that defines what claims you give up in exchange for compensation. In any class action settlement, the release is the price of admission. But the objecting firms suggest that the release provisions in this deal may be too broad, potentially requiring some class members to waive important legal rights for uncertain or limited payments. This is not an abstract concern.
In prior mass tort settlements, overly broad releases have prevented plaintiffs from bringing related claims — for example, claims based on newly discovered health effects or claims against other parties in the supply chain. If the Roundup settlement release extends to future claims or to entities beyond Bayer, claimants could find themselves locked out of legal remedies they do not yet know they need. The warning here is straightforward: do not assume that a class action settlement only affects the specific claim you filed. Read the release language carefully, or have your attorney explain it to you in plain terms. If you are an absent class member — someone exposed to Roundup who has not yet been diagnosed with cancer — the release provisions are even more critical, because you may be giving up the right to sue over a disease you have not yet developed.
Bayer’s Position and the Road to Final Approval
Bayer has publicly stated that it “remained confident that the proposed settlement was fair to all claimants, and warrants approval by the court.” That confidence is not surprising — the company has been trying to resolve its Roundup liability for years, and a $7.25 billion settlement covering 65,000 claims and a 21-year exposure window would represent a significant step toward closing the book on glyphosate litigation. But confidence from the defendant is not the same as fairness to plaintiffs.
The court’s role in reviewing a class action settlement is to act as a fiduciary for absent class members, ensuring that the deal is reasonable and that the process was adequate. Whether Judge Boyer decides to grant the 60-day extension or push forward with the March timeline will signal how seriously the court takes the procedural objections — and could set the tone for the entire approval process.
What Happens Next and Why It Matters Beyond Roundup
The outcome of this dispute will resonate well beyond Roundup litigation. If the court allows a $7.25 billion settlement to move toward preliminary approval just 15 days after it was announced, with objections from firms representing 20,000 plaintiffs effectively sidelined, it would set a troubling precedent for future mass tort settlements. Speed should not come at the expense of due process, particularly when the rights of tens of thousands of cancer patients and future claimants are at stake.
On the other hand, if Judge Boyer grants the 60-day extension, it opens the door for meaningful scrutiny of the settlement terms, the compensation tiers, and the release provisions. That additional time could lead to modifications that better protect all class members — or it could lead to the settlement unraveling entirely if the objections prove too fundamental to resolve. Either way, the next few weeks in St. Louis City Circuit Court will be pivotal for anyone affected by Roundup exposure.
Frequently Asked Questions
How much money could I receive from the Roundup settlement?
It depends on your exposure type and diagnosis. Under the proposed terms, an occupational claimant diagnosed with aggressive non-Hodgkin lymphoma before age 60 could average $165,000, while a residential user with the same diagnosis could average $40,000. Individual amounts will vary based on the settlement’s tier structure and allocation formulas.
Has the Roundup settlement been approved by the court?
No. As of late February 2026, the settlement has not received even preliminary approval. A hearing had been tentatively scheduled for as early as March 4, 2026, but 14 law firms have filed a motion requesting a 60-day delay. Judge Timothy Boyer in St. Louis City Circuit Court has not yet ruled on that motion.
Can I opt out of the Roundup settlement?
If the settlement receives preliminary approval, class members will be notified and given the option to opt out and pursue their own individual lawsuits. Opt-out deadlines in class action settlements are strict, so it is critical to read any official notice you receive and respond before the deadline.
What if I was exposed to Roundup but have not been diagnosed with cancer?
You may still be considered a class member under this settlement, which covers a 21-year exposure period and includes future cancer claimants. This is one of the most controversial aspects of the deal — your future legal rights could be affected even if you are currently healthy. Consult an attorney if you have concerns about your exposure history.
Why are attorneys objecting to the settlement?
The 14 objecting firms cite several concerns: the deal was negotiated without input from many plaintiffs’ attorneys, the compensation tiers show significant disparities, the release provisions may be too broad, and attorneys received the 600-page settlement package with inadequate time for review before the proposed approval hearing.
Does the settlement affect Roundup lawsuits that are already in court?
If preliminary approval is granted, it would trigger a broad stay of all Roundup litigation, including cases that have been pending for years. This means trials and other proceedings would be paused while the settlement process moves forward, potentially adding further delays for plaintiffs who have already waited a long time.